• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oramed may discontinue oral insulin activity for type 2 diabetes after trial misses endpoints

January 12, 2023 By Sean Whooley

Oramed LogoOramed Pharmaceuticals (Nasdaq:ORMP) announced that top-line Phase 3 trial results for its oral insulin candidate missed its endpoints.

The Phase 3, randomized, double-blind, placebo-controlled trial compared the efficacy of ORMD-0801 to placebo. It evaluated patients with type 2 diabetes at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control. Those patients were also on two or three oral glucose-lowering agents.

Oramed’s trial failed to meet its primary endpoint comparing efficacy in improving glycemic control. It assessed efficacy by the mean change from baseline in A1C at 26 weeks.

The trial also failed to meet its secondary endpoint of the mean change from baseline in fasting plasma glucose at 26 weeks. It recorded no serious drug-related adverse events. Oramed said it expects to discontinue its oral insulin clinical activities for T2D.

“Today’s outcome is very disappointing, given the positive results from prior trials,” said Oramed CEO Nadav Kidron. “Once full data from the studies are available, we expect to share relevant learnings and future plans. We thank all the patients, families and healthcare professionals who participated in the trial.”

Oramed aims to change the treatment of diabetes with its ORMD-0801 oral insulin capsule. The capsule is currently under evaluation in a second pivotal Phase 3 trial. The company recently inked a deal to commercialize the oral insulin treatment in the Republic of Korea. It also picked up a new patent for its oral diabetes treatment earlier this month.

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Pharmaceuticals Tagged With: oramedpharmaceuticals

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS